Bin Wu

发表

Interventions for reducing inflammation in familial Mediterranean fever.

Ting Xu, Youping Li, Bin Wu, 2018, The Cochrane database of systematic reviews.

Interventions for reducing inflammation in familial Mediterranean fever.

Ting Xu, Youping Li, Bin Wu, 2015, The Cochrane database of systematic reviews.

Xiaodan Li, N. Su, Ting Xu, 2022, Frontiers in Endocrinology.

Sulodexide for treating venous leg ulcers.

Bin Wu, T. Xu, Jing Lu, 2016, The Cochrane database of systematic reviews.

Development of a trigger tool for the detection of adverse drug events in Chinese geriatric inpatients using the Delphi method

Ting Xu, Bin Wu, M. Zhan, 2019, International Journal of Clinical Pharmacy.

Sex differences in immune-related adverse events with immune checkpoint inhibitors: data mining of the FDA adverse event reporting system

Bin Wu, Chen Chen, Chenyu Zhang, 2022, International Journal of Clinical Pharmacy.

Interventions for reducing inflammation in familial Mediterranean fever.

Ting Xu, Bin Wu, Xianya Yin, 2022, The Cochrane database of systematic reviews.

An observational, retrospective, comprehensive pharmacovigilance analysis of hydroxychloroquine-associated cardiovascular adverse events in patients with and without COVID-19

Fengbo Wu, Bin Wu, Min Luo, 2022, International Journal of Clinical Pharmacy.

Dapagliflozin treatment for type 2 diabetes: a systematic review and meta‐analysis of randomized controlled trials

Shuangqing Li, Z. An, Mei Zhang, 2014, Diabetes/metabolism research and reviews.

Angiotensin receptor-neprilysin inhibitor and sodium-dependent glucose cotransporter-2 inhibitor-associated renal injury: a pharmacovigilance study

Bin Wu, Chen Chen, Chenyu Zhang, 2022, Expert opinion on drug safety.

Predicting adverse drug events in older inpatients: a machine learning study

Ting Xu, Bin Wu, Qiaozhi Hu, 2022, International Journal of Clinical Pharmacy.

Bin Wu, Chen Chen, Chenyu Zhang, 2022, Journal of geriatric oncology.

An observational, retrospective, comprehensive pharmacovigilance analysis of hydroxychloroquine-associated cardiovascular adverse events in patients with and without COVID-19

Fengbo Wu, Bin Wu, Min Luo, 2022, International Journal of Clinical Pharmacy.

Exploration and practice of methods and processes of evidence‐based rapid review on peer review of WHO EML application

J. Kwong, Xin Sun, J. Kwong, 2015, Journal of evidence-based medicine.

Association Between Genetic Polymorphisms of Metabolic Enzymes and Azathioprine-Induced Myelosuppression in 1,419 Chinese Patients: A Retrospective Study

Zhi-Yao He, Ting Xu, Rui Zhang, 2021, Frontiers in Pharmacology.

Chenyu Zhang, Ting Xu, Bin Wu, 2021, International immunopharmacology.

Cardiotoxicity with human epidermal growth factor receptor-2 inhibitors in breast cancer: Disproportionality analysis of the FDA adverse event reporting system.

Bin Wu, F. Tian, Chen Chen, 2023, International journal of cardiology.

Analysis of adverse event of interstitial lung disease in men with prostate cancer receiving hormone therapy using the Food and Drug Administration Adverse Event Reporting System

Fengbo Wu, Jian Li, P. Shen, 2022, British journal of clinical pharmacology.

Proton pump inhibitors associated acute kidney injury and chronic kidney disease: data mining of US FDA adverse event reporting system

Zhiyao He, Ting Xu, Bin Wu, 2021, Scientific Reports.

Effectiveness and safety of adjunctive inhaled antibiotics for ventilator-associated pneumonia: A systematic review and meta-analysis of randomized controlled trials.

R. Tang, Bin Wu, Fu-Sheng Wang, 2021, Journal of critical care.

Acute Kidney Injury Associated With Remdesivir: A Comprehensive Pharmacovigilance Analysis of COVID-19 Reports in FAERS

Zhiyao He, Fengbo Wu, Bin Wu, 2022, Frontiers in Pharmacology.

A pharmacovigilance study of association between proton pump inhibitor and dementia event based on FDA adverse event reporting system data

Ting Xu, Fengbo Wu, Bin Wu, 2021, Scientific Reports.

Development and validation of a nomogram to predict the risk of potentially inappropriate medication use in older lung cancer outpatients with multimorbidity.

Bin Wu, F. Tian, Zhaoyan Chen, 2023, Expert opinion on drug safety.

Heparin for the treatment of burns

Bin Wu, T. Xu, Jing Lu, 2011 .

Reporting of Drug-Induced Myopathies Associated with the Combination of Statins and Daptomycin: A Disproportionality Analysis Using the US Food and Drug Administration Adverse Event Reporting System

Zhiyao He, W. Yin, Bin Wu, 2023, Journal of clinical medicine.

A real-world pharmacovigilance study of severe cutaneous adverse reactions associated with antiepileptic drug combination therapy: data mining of FDA adverse event reporting system

Yin Liu, W. Yin, Bin Wu, 2022, Expert Opinion on Drug Safety.

Adverse events identified by the global trigger tool at a university hospital: A retrospective medical record review

Ting Xu, Bin Wu, M. Zhan, 2018, Journal of evidence-based medicine.

Validating the Chinese geriatric trigger tool and analyzing adverse drug event associated risk factors in elderly Chinese patients: A retrospective review

Ting Xu, Bin Wu, M. Zhan, 2020, PloS one.

N. Tong, Liang Du, Bin Wu, 2014 .

A pharmacovigilance study of the association between antipsychotic drugs and venous thromboembolism based on Food and Drug Administration Adverse Event Reporting System data

Ling Wang, Bin Wu, Jiayue Xu, 2023, Expert opinion on drug safety.

Interventions for reducing inflammation in familial Mediterranean fever.

Ting Xu, Bin Wu, Xianya Yin, 2022, The Cochrane database of systematic reviews.

Analysis of the association between Janus kinase inhibitors and malignant skin tumors using the Food and Drug Administration Adverse Event Reporting System

Bin Wu, Li Li, Ruonan Gao, 2023, International Journal of Clinical Pharmacy.

Cardiovascular Safety Evaluation of Febuxostat and Allopurinol: Findings from the FDA Adverse Event Reporting System

Bin Wu, Yuwen Li, Ting Xu, 2023, Journal of clinical medicine.